BB Biotech (SWX:BION) ended the first half with its shares up 22.2% and at CHF87 at the close yesterday, just 5% below their all-time high of CHF90 that was reached in February. The Swiss investment company’s net asset value grew by 8.9% in the first half to CHF73.1 per share, which seems to be a […]
BB Biotech (SWX:BION) increased its stake in the US cancer biotech MacroGenics by a fifth just over a week ago, seemingly taking advantage of a fall in the company’s share price in the wake of the ASCO scientific meeting earlier this month. Hitherto, MacroGenics ranked in tenth position in BB Biotech’s portfolio, accounting for 3.6% […]
BB Biotech’s large bet on the US regulatory approval of Biogen’s Alzheimer’s disease therapy aducanumab has met with success, after the FDA rendered an approval in a landmark, although highly controversial, decision yesterday. The news prompted a huge rise in Biogen’s share price (Nasdaq: BIIB), which closed 38% up at $395/share, having peaked at $450 […]
Two of BB Biotech’s holdings were among the largest movers – one up and one down – on Friday, the first day of ASCO – the American Society of Clinical Oncology – when stocks responded to an avalanche of updated clinical trial data released at the start of the virtual scientific meeting. Fate Therapeutics, BB […]
BB Biotech’s bet on a positive US regulatory review of Biogen’s controversial Alzheimer’s disease therapy aducanumab is poised for its denouement, with the PDUFA date – the deadline for the FDA to render an approval decision – now less than two weeks away. The Swiss investment firm acquired a stake in Biogen (accounting for 3.3% […]
A 2020 vintage investment for Switzerland’s BB Biotech has turned out to be one of the highest profile victims of the stock price moves occasioned by the ASCO abstract release earlier this week. Black Diamond Therapeutics (Nasdaq: BDTX) saw its shares fall by 37% yesterday after early-stage results of its lead compound BDTX-189 – although […]
Shares in the US Covid vaccine developer Moderna – the second largest holding for giant Swiss investment company BB Biotech – fell by 6% yesterday, after the Biden Administration said it would support an exceptional waiver of IP protection on COVID-19 vaccines for developing countries through the World Trade Organisation. Moderna accounted for 7.8% of […]
Swiss investor BB Biotech made two new investments in the first quarter in US small caps – Essa Pharma and Revolution Medicines – while exiting its positions in Cidara Therapeutics and Voyager Therapeutics, according to its portfolio update published earlier today. Essa Pharma (Nasdaq: EPIX) is developing a small molecule drug, EPI-7386, in metastatic castration-resistant […]
Biotech Growth tops bio-trust league with 47% NAV rise – Orbimed-managed Biotech Growth Trust (BIOG) recorded the rise 47% rise in NAV in 2019, representing the best performance of the 14 specialist biotech/pharma closed end investment vehicles monitored by Marten & Co. Biotech Growth’s rise in NAV was more than double that of the benchmark […]
BioPharma Credit loan to Sarepta, as FDA approves Vyondys BioPharma Credit (BPCR), the LSE-listed life sciences debt investor, is to extend a loan of up to $350m to the US listed biotech, Sarepta Therapeutics (Nasdaq: SRPT), as part of a $500m senior secured term loan arranged by its manager Pharmakon Advisors, with the remainder provided […]